West Pharmaceutical Services Elects New Directors
Ticker: WST · Form: 8-K · Filed: Dec 11, 2024 · CIK: 105770
Sentiment: neutral
Topics: board-changes, governance, disclosure
TL;DR
West Pharma adds 2 new directors to the board, effective Dec 9, 2024.
AI Summary
On December 9, 2024, West Pharmaceutical Services, Inc. announced the election of two new directors, Dr. Steven A. Muchmore and Ms. Karen L. King, to its Board of Directors. The company also disclosed compensatory arrangements for its named executive officers and provided a Regulation FD disclosure. This filing is a current report under the Securities Exchange Act of 1934.
Why It Matters
The addition of new directors can signal strategic shifts or a response to evolving governance needs within the company.
Risk Assessment
Risk Level: low — This filing primarily concerns board appointments and standard disclosures, with no immediate financial or operational risks indicated.
Key Players & Entities
- WEST PHARMACEUTICAL SERVICES, INC. (company) — Registrant
- Dr. Steven A. Muchmore (person) — Newly elected director
- Ms. Karen L. King (person) — Newly elected director
- December 9, 2024 (date) — Date of earliest event reported
FAQ
Who were the new directors elected to West Pharmaceutical Services' Board?
Dr. Steven A. Muchmore and Ms. Karen L. King were elected as new directors.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is December 9, 2024.
What type of filing is this for West Pharmaceutical Services?
This is a Form 8-K Current Report filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
What are the main items disclosed in this 8-K filing?
The filing includes the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, Regulation FD Disclosure, and Financial Statements and Exhibits.
What is the principal executive office address for West Pharmaceutical Services?
The principal executive offices are located at 530 Herman O. West Drive, Exton, PA 19341-1147.
Filing Stats: 923 words · 4 min read · ~3 pages · Grade level 9.9 · Accepted 2024-12-11 16:11:22
Key Financial Figures
- $0.25 — ich registered Common Stock, par value $0.25 per share WST New York Stock Exchange
- $100,000 — irectors, which currently consists of a $100,000 annual retainer and an annual restricte
- $220,000 — n annual restricted stock unit grant of $220,000. Each element of Ms. Haugen's compensat
Filing Documents
- wst-20241209.htm (8-K) — 37KB
- exh99112-2024directorappoi.htm (EX-99.1) — 9KB
- wst-20241209_g1.jpg (GRAPHIC) — 17KB
- wstlogoq319.jpg (GRAPHIC) — 17KB
- 0000105770-24-000084.txt ( ) — 242KB
- wst-20241209.xsd (EX-101.SCH) — 2KB
- wst-20241209_lab.xml (EX-101.LAB) — 21KB
- wst-20241209_pre.xml (EX-101.PRE) — 12KB
- wst-20241209_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On December 11, 2024, the Company issued a press release announcing the appointment of Ms. Haugen to the Board. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibit No. Description 99.1 West Pharmaceutical Services, Inc. Press Release, dated December 11, 2024 104 The cover page from the Company's Current Report on Form 8-K, dated December 9, 2024, formatted in Inline XBRL. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. WEST PHARMACEUTICAL SERVICES, INC. /s/ Bernard J. Birkett Bernard J. Birkett Senior Vice President, Chief Financial Officer December 11, 2024 3 EXHIBIT INDEX Exhibit No. Description 99.1 West Pharmaceutical Services, Inc. Press Release, dated December 11, 2024 . 104 The cover page from the Company's Current Report on Form 8-K, dated December 9, 2024, formatted in Inline XBRL. 4